Prothrombin 20210GA and factor V Leiden mutations in patients less than 55 years old with myocardial infarction.

Yurdaer Dönmez, Mehmet Kanadasi, Kahraman Tanriverdi, Mesut Demir, Mustafa Demirtas, Murat Cayli, Cumhur Alhan, Fikri Baslamisli
{"title":"Prothrombin 20210GA and factor V Leiden mutations in patients less than 55 years old with myocardial infarction.","authors":"Yurdaer Dönmez,&nbsp;Mehmet Kanadasi,&nbsp;Kahraman Tanriverdi,&nbsp;Mesut Demir,&nbsp;Mustafa Demirtas,&nbsp;Murat Cayli,&nbsp;Cumhur Alhan,&nbsp;Fikri Baslamisli","doi":"10.1536/jhj.45.505","DOIUrl":null,"url":null,"abstract":"<p><p>Several studies claim that prothrombin 20210GA and factor V Leiden mutations are related to arterial thrombosis. We investigated the frequencies of these mutations and their significance in the development of early atherosclerosis in acute myocardial infarction (AMI) patients younger than 55 years of age. We investigated 96 patients with AMI and 77 control subjects. The diagnosis of AMI was established by typical chest pain and ST elevations on the presentation electrocardiogram and characteristic cardiac enzyme elevations. None of the control subjects had evidence of cardiovascular disease. DNA samples were isolated from all subjects and prothrombin 20210GA and factor V Leiden mutations were determined by the RealTime PCR technique with the aid of a Light Cycler device. The prevalence of factor V Leiden mutation was 6.3% and 5.2% in the patient and control groups, respectively (OR 0.6 [95% CI 0.1- 3.9], P = 0.6), whereas the prevalence of prothrombin G20210A mutation was 4.2% and 2.6% in the patient and control groups, respectively (OR 2.8 [95% CI 0.2 - 32.2], P = 0.4). None of the patients had both mutations. Prothrombin 20210GA and factor V Leiden mutations are not significant risk factors for the development of myocardial infarction in patients less than 55 years old in Southern Turkey.</p>","PeriodicalId":14717,"journal":{"name":"Japanese heart journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2004-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1536/jhj.45.505","citationCount":"32","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese heart journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1536/jhj.45.505","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 32

Abstract

Several studies claim that prothrombin 20210GA and factor V Leiden mutations are related to arterial thrombosis. We investigated the frequencies of these mutations and their significance in the development of early atherosclerosis in acute myocardial infarction (AMI) patients younger than 55 years of age. We investigated 96 patients with AMI and 77 control subjects. The diagnosis of AMI was established by typical chest pain and ST elevations on the presentation electrocardiogram and characteristic cardiac enzyme elevations. None of the control subjects had evidence of cardiovascular disease. DNA samples were isolated from all subjects and prothrombin 20210GA and factor V Leiden mutations were determined by the RealTime PCR technique with the aid of a Light Cycler device. The prevalence of factor V Leiden mutation was 6.3% and 5.2% in the patient and control groups, respectively (OR 0.6 [95% CI 0.1- 3.9], P = 0.6), whereas the prevalence of prothrombin G20210A mutation was 4.2% and 2.6% in the patient and control groups, respectively (OR 2.8 [95% CI 0.2 - 32.2], P = 0.4). None of the patients had both mutations. Prothrombin 20210GA and factor V Leiden mutations are not significant risk factors for the development of myocardial infarction in patients less than 55 years old in Southern Turkey.

55岁以下心肌梗死患者凝血酶原20210GA和因子V Leiden突变
多项研究认为凝血酶原20210GA和V - Leiden因子突变与动脉血栓形成有关。我们研究了这些突变的频率及其在55岁以下急性心肌梗死(AMI)患者早期动脉粥样硬化发展中的意义。我们调查了96例AMI患者和77例对照组。AMI的诊断是通过典型的胸痛和心电图上的ST段升高和特征性的心酶升高来确定的。没有一个对照组有心血管疾病的证据。从所有受试者中分离DNA样本,在Light Cycler装置的辅助下,采用RealTime PCR技术检测凝血酶原20210GA和V - Leiden因子突变。V Leiden因子突变在患者组和对照组的患病率分别为6.3%和5.2% (OR 0.6 [95% CI 0.1 ~ 3.9], P = 0.6),而凝血酶原G20210A突变在患者组和对照组的患病率分别为4.2%和2.6% (OR 2.8 [95% CI 0.2 ~ 32.2], P = 0.4)。没有一个患者同时具有这两种突变。在土耳其南部,凝血酶原20210GA和因子V Leiden突变不是55岁以下患者发生心肌梗死的显著危险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信